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60Epidemiology of COVID-19 Infection. Multiple logistic
regression was used to assess the association between clinical
and/or demographic characteristics and hospitalization.
A separate patient-facing registry characterized risk-mitigating
behaviors.
Results: Of 374 clinician-reported patients from 25 countries,
71% were receiving a biologic, 18% were receiving a
nonbiologic, and 10% were not receiving any systemic
treatment for psoriasis. In all, 348 patients (93%) were fully
recovered from COVID-19, 77 (21%) were hospitalized, and 9*These authors are joint first authors.
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MAHIL ET AL 61(2%) died. Increased hospitalization risk was associated with
older age (multivariable-adjusted odds ratio [OR] 5 1.59 per 10
years; 95% CI 5 1.19-2.13), male sex (OR 5 2.51; 95% CI 5
1.23-5.12), nonwhite ethnicity (OR5 3.15; 95% CI5 1.24-8.03),
and comorbid chronic lung disease (OR 5 3.87; 95% CI 5 1.52-
9.83). Hospitalization was more frequent in patients using
nonbiologic systemic therapy than in those using biologics
(OR 5 2.84; 95% CI 5 1.31-6.18). No significant differences
were found between classes of biologics. Independent patient-
reported data (n 5 1626 across 48 countries) suggested lower
levels of social isolation in individuals receiving nonbiologic
systemic therapy than in those receiving biologics (OR 5 0.68;
95% CI 5 0.50-0.94).
Conclusion: In this international case series of patients with
moderate-to-severe psoriasis, biologic use was associated with
lower risk of COVID-19–related hospitalization than with use of
nonbiologic systemic therapies; however, further investigation is
warranted on account of potential selection bias and
unmeasured confounding. Established risk factors (being older,
being male, being of nonwhite ethnicity, and having
comorbidities) were associated with higher hospitalization rates.
(J Allergy Clin Immunol 2021;147:60-71.)
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62 MAHIL ET ALresponses prevents further viral replication, T-cell exhaustion, and
hyperinflammation.13 A reduced or delayed type I IFN response
has been associated with poor COVID-19 outcomes14; thus, it is
possible that the immune dysregulation in psoriasis may be advan-
tageous, although its therapeutic suppression may be detrimental.
The second phase of COVID-19 comprises hyperinflammation
and cytokine storm, with elevation of proinflammatory cytokines
also implicated in psoriasis, including TNF, IL-1b, IL-6, IL-8,
IFN-g, and IL-17. It is unclear whether individuals with psoriasis
are at greater risk of progression to this phase, and conversely,
whetherdrugs that affect the immune system(biologics and standard
systemicagents) are effective therapies for severeCOVID-19.Treat-
ments targeting the overexuberant host immune response in
COVID-19, including inhibitors of IL-1, IL-6, Janus kinase, and
TNF, are currently undergoing clinical trial.15,16
Psoriasis, rheumatoid arthritis, and SLE were collectively
highlighted as potential risk factors for COVID-19–related death
through use of primary care data linked to hospital records from
17 million adults in the United Kingdom.6 However, the risk
attributed to psoriasis alone or its therapies remains uncertain.
Preliminary reports in individuals with psoriasis have not demon-
strated higher levels of COVID-19–related hospitalization among
those receiving biologic therapies.17-20 However, these data have
limited external validity because the case series were all from
Northern Italy and included few patients with adverse outcomes.
There is thus an urgent need to collate reports of COVID-19 in pa-
tients with psoriasis to understand the determinants of severe
infection and help inform clinical decision making. Here, we
have described the first international series of patients with psori-
asis and COVID-19 and identified demographic and clinical fac-
tors associated with hospitalization.METHODS
Study design, setting, and participants
This registry-based study used 2 data sources. The primary data source was
an online clinician-reported registry, Psoriasis Patient Registry for Outcomes,
Therapy and Epidemiology of COVID-19 Infection (PsoProtect), which
launched globally on March 27, 2020.21 Data were collected and managed
by using Research Electronic Data Capture (REDCap) electronic data capture
tools licensed to the King’s College London Division of Health and Social
Care Research.22,23 REDCap is a secure, web-based software platform de-
signed to support data capture.
The eligibility criterion was any patient with psoriasis and confirmed or
suspected COVID-19 identified by his or her supervising clinician. Case
submission was requested at least 14 days following onset of symptoms and
once sufficient time had passed to observe the outcome of infection. Clinicians
were invited to participate via the communication channels of multiple
international professional organizations (see Table E1 in this article’s Online
Repository at www.jacionline.org). We also invited case reports from 2 US
COVID-19 registries (SECURE-Psoriasis and American Academy of Derma-
tology COVID-19 [AAD COVID-19]).24,25 In all, 38 of the cases have been
published elsewhere (n 52917 and n 5 918).
The second data source was a separate online self-report patient-facing
registry, PsoProtectMe, which launched globally on May 4, 2020. The eligibility
criterionwas a clinician-confirmed diagnosis of psoriasis, irrespective of COVID-
19 status. Participants were invited via the communication channels of multiple
international organizations focused on individuals with psoriasis (see Table E1).Variables
Minimum sufficient core sets of variables within the PsoProtect and
PsoProtectMe case report forms26,27 were defined by our study group ofclinicians, epidemiologists, health data researchers, and patient representa-
tives aligned with those of other immune-mediated inflammatory disease
(IMID) COVID-19 registries.28,29 Key variables in both registries included de-
mographics (age, sex, ethnicity, and country), smoking status, comorbidities,
details of psoriasis (phenotype and treatment) and COVID-19 (symptoms,
treatment, and outcome). Medication adherence and social isolation behavior
during the pandemic were collected in PsoProtectMe.Statistical methods
PsoProtect and PsoProtectMe data were extracted on July 1 and 3, 2020,
respectively. Incomplete, duplicate, and erroneous entries were manually re-
viewed by the study team and removed. All analysis was performed by using
the R statistical programming language.30
Demographic and clinical characteristics and COVID-19 outcomes of the
study population were summarized by using descriptive statistics. Continuous
variables were reported by using median and interquartile range (IQR), and
categoric/dichotomous variables were reported as number and percentage.
We used clinician-reported registry data to investigate the demographic and
disease-specific factors associated with the primary outcome of hospitaliza-
tion for COVID-19. The key exposure measure was treatment type for
psoriasis at or up to 4 weeks before COVID-19 onset, comprising biologics
(the TNF inhibitors adalimumab, certolizumab pegol, etanercept, infliximab,
and golimumab; the IL-17 inhibitors brodalumab, ixekizumab, secukinumab;
the IL12/IL-23p40 or IL-23p19 [collectively IL-23] inhibitors guselkumab,
risankizumab, tildrakizumab, and ustekinumab), nonbiologic systemic agents
(acitretin, apremilast, ciclosporin, methotrexate, fumaric acid esters/dime-
thylfumarate, and prednisolone), and no systemic treatment.
The association between treatment type (biologic, nonbiologic systemic, or
no systemic treatment) and hospitalization for COVID-19 was assessed by
using (1) a minimally adjusted logistic regression model that included age and
sex covariates and (2) a fully adjusted model that included a consensus list of
covariates selected a priori as potentially influential on adverse COVID-19
outcome on the basis of expert clinical opinion and existing evidence,2,3,6,31
namely, age, sex, ethnicity, country, smoking, bodymass index (BMI), and co-
morbidities. Other relevant variables (use of an angiotensin-converting
enzyme inhibitor, use of an angiotensin II receptor blocker, and obesity as a
comorbidity) that correlated (jrj > 0.5) with included covariates were
excluded. Levels of categoric variables exhibiting small counts (<10 observa-
tions of either outcome) weremerged. Comorbid obesity was assumed in cases
inwhich BMIwas 30 or higher, evenwhen not directly reported. Selection bias
inmissing data was explored by comparing patients withmissing data for vari-
ables included in the fully adjusted model (BMI, smoking, or BMI and smok-
ing) with patients with complete data (see Table E2 in this article’s Online
Repository at www.jacionline.org). Small differences were observed in the
proportions of men, white ethnicity, confirmed COVID-19 diagnosis, and hos-
pitalization. Therefore, to maximize the included data, the final regression
models were based on 20multiply imputed data sets generated with the R soft-
ware package Multivariate Imputation by Chained Equations (MICE).32
Quadratic terms for age and sex covariates were considered but rejected
owing to lack of improvement in model fit (likelihood ratio test). Minimally
and fully adjusted odds ratios (ORs) and 95% CIs were reported for each
variable. Sensitivity analyses were performed on the fully adjusted multivari-
able regression models. To assess the association between biologic class and
the primary outcome, we fitted a fully adjusted model in which treatment type
was further categorized by biologic class (TNF, IL-17, or IL-23 inhibitor).
Improvement in fit relative to the original treatment type model was assessed
by using a likelihood ratio test. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement for cross-
sectional studies was used as a basis for reporting.33Ethical approval
Ethical approval was granted by the Leeds Research Ethics Committee (20/
YH/0135), and the study was registered in the European Union electronic
Register of Post-Authorisation Studies.34 Only de-identified data were
collected; hence, written informed patient consent was not required. Data
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International Council for Harmonization Good Clinical Practice, and the Eu-
ropean Union General Data Protection Regulation.RESULTS
Demographic and clinical characteristics of a global
series of individuals with COVID-19 and psoriasis
In total, 374 patients with psoriasis and confirmed (n 5 172
[46%]) or suspected (n 5 202 [54%]) COVID-19 were reported
by clinicians from 25 countries (including the United Kingdom
[n5 135 (36%)], Italy [n5 80 (21%)], and Spain [n5 56 (15%)]
[see Table E3 in this article’s Online Repository at www.
jacionline.org]). Demographic and clinical characteristics are
summarized in Table I. The median age was 50 years (IQR 5
41-58). There was a predominance of males (n 5 227 [61%])
and individuals of white ethnicity (n 5 316 [85%]). Among
304 patients with known smoking status, 165 (54%) had never
smoked and 44 (15%) were current smokers. The majority of pa-
tients had plaque psoriasis (n 5 365 [98%]) and clear, nearly
clear, or mild psoriasis at COVID-19 onset (n 5 298 [80%]).
The most commonly reported comorbidities were obesity (n 5
123 [33%]), hypertension (n 5 97 [26%]), psoriatic arthritis
(n 5 96 [26%]), and diabetes (n 5 61 [16%]).
Most patients were receiving a biologic treatment (n 5 267
[71%]) for their psoriasis rather than a nonbiologic systemic agent
(n5 67 [18%]) or no systemic therapy (n5 36 [10%]). Of those
receiving a biologic, similar numbers of patients were receiving
either a TNF, IL-17, or IL-23 inhibitor (n 5 99, 78, and 90,
respectively). Demographic and clinical characteristics by bio-
logic class are summarized in Table E4 (in this article’s Online
Repository at www.jacionline.org) and split by confirmed and
suspected COVID-19 in Table E5 (in this article’s Online Repos-
itory at www.jacionline.org).Most reported patients fully recovered from
COVID-19
Of the reported patients, 348 (93%) fully recovered from
COVID-19 (Table II). The most common COVID-19 symptoms
were fever (n 5 244 [68%]), fatigue (n 5 174 [48%]), and dry
continuous cough (n5 167 [46%]); the median duration of symp-
toms was 14 days (IQR 5 7-21).
In all, 77 patients (21%) were hospitalized for COVID-19, 7
(2%) required high-flow oxygen supplementation and 12 (3%)
required mechanical ventilation. The median length of hospital
stay was 11 days (IQR 5 6-20). A total of 9 patients died (2%);
their median age was 65 years (range 43-89 years), and all had at
least 1 comorbidity, with hypertension (n5 6 [67%]) and diabetes
(n5 5 [56%]) being the most prevalent. COVID-19 outcomes by
biologic class. The data for these patients are summarized in
Table E6 (in this article’s Online Repository at www.jacionline.
org) and split by confirmed and suspected COVID-19 in Table
E7 (in this article’s Online Repository at www.jacionline.org).Rates of hospitalization differed by psoriasis
treatment type, in addition to established risk
factors for COVID-19
After exclusion of 9 individuals because of unknown drug type
(clinical trial participants), unknown hospitalization status, orunknown COVID-19 outcome, 365 patients with psoriasis were
available to assess factors associated with hospitalization. Rates
of hospitalization for COVID-19 were higher among males (26%
vs 12% among females), older patients (60% among those older
than 70 years vs 26% among those aged 50-70 years and 10% of
those younger than 50 years), and nonwhite ethnicity (32% versus
19% among individuals of white ethnicity). Comorbidities were
also highly prevalent: 76% of hospitalized patients were reported
to have hypertension, cardiovascular disease, diabetes, chronic
liver disease, or chronic lung disease (including asthma)
compared with 34% of nonhospitalized patients.
Hospitalization for COVID-19 was less common among
patients receiving biologic therapy for their psoriasis (<_4 weeks
before COVID-19 onset; 44 of 265 [17%]) than among those
receiving nonbiologic systemic therapy (22 of 65 [34%]) or no
systemic therapy (10 of 35 [29%]). Patients receiving biologic
therapy also had lower rates of mechanical ventilation (3% vs 5%
among those receiving nonbiologics) and death (2% vs 5%).
Compared with the reference group of biologic users, an age-
and sex-adjusted model for hospitalization rate estimated an OR
of 2.72 for nonbiologic systemic users and a 95% CI that did not
cross unity (1.37-5.40) (Table III).
To account for potential confounding from a range of
established COVID-19 risk factors, a fully adjusted multivariable
logistic regression model was fitted (Table III). Significant asso-
ciations with increased hospitalization rate were observed for
age (OR 5 1.59 per 10 years; 95% CI 5 1.19-2.13), male sex
(OR 5 2.51; 95% CI 5 1.23-5.12), nonwhite ethnicity (OR 5
3.15; 95% CI 5 1.24-8.03), and comorbid chronic lung disease
(OR 5 3.87; 95% CI 5 1.52-9.83). Despite imprecise 95% CIs,
elevated risk of hospitalization was suggested for several comor-
bidities with ORs greater than 2: hypertension (OR5 2.03; 95%
CI 5 0.99-4.16), cardiovascular disease (OR 5 2.01; 95% CI 5
0.74-5.46), and chronic liver disease (OR5 2.12; 95%CI5 0.81-
5.55). No association was found with ever having smoked (OR5
1.16; 95% CI 5 0.54-2.49).
In the fully adjusted model, use of a nonbiologic systemic
therapy for psoriasis remained associated with increased risk of
hospitalization compared with use of a biologic (OR5 2.84; 95%
CI 5 1.31-6.18). Patients receiving no systemic therapy were
estimated to have a similarly increased risk of hospitalization
(OR 5 2.35; 95% CI 5 0.82-6.72). This suggests that use of
biologics is associated with a reduced risk of hospitalization
compared with either nonbiologic systemic therapy or no therapy,
although interpretation of these estimates should take into
account possible sources of bias (as detailed in the Discussion
section).
Patients reported in Spain were more likely to have been
hospitalized for COVID-19 (43% vs 17% elsewhere) and more
likely to have received a nonbiologic systemic agent (30% vs
16% elsewhere), which could potentially confound the estimated
association between treatment type and hospitalization. Although
country of assessment was included in the fully adjusted model
(Spain OR5 4.79; 95% CI5 1.88-12.19), a sensitivity test using
only non-Spanish patients identified broadly similar effect size
estimates for treatment type (see Table E8 in this article’s Online
Repository at www.jacionline.org). A multiple regression model
fitted in confirmed cases only (see Table E9 in this article’s Online
Repository at www.jacionline.org) indicated a stronger associa-
tion with hospitalization risk for use of nonbiologic systemic
agents than with hospitalization risk for use of biologics








no systemic agent Missing
(no.)(n 5 374) (n 5 267) (n 5 67) (n 5 36)
Sex, no. (%) 0
Female 147 (39.3) 107 (40.1) 29 (43.3) 9 (25.0)
Male 227 (60.7) 160 (59.9) 38 (56.7) 27 (75.0)
Age (y), median (IQR) 50 (41-58) 50 (42-57) 49 (40-60) 53 (35-63) 0
Ethnicity, no. (%) 3
White 316 (85.2) 230 (86.5) 57 (86.4) 27 (77.1)
South Asian 21 (5.7) 16 (6.0) 3 (4.5) 2 (5.7)
Hispanic or Latino 19 (5.1) 13 (4.9) 3 (4.5) 1 (2.9)
Other 15 (4.0) 7 (2.6) 3 (4.5) 5 (14.3)
Country of assessment, no. (%) 0
United Kingdom 135 (36.1) 103 (38.6) 21 (31.3) 11 (30.6)
Italy 80 (21.4) 69 (25.8) 11 (16.4) 0 (0.0)
Spain 56 (15.0) 35 (13.1) 16 (23.9) 3 (8.3)
United States 25 (6.7) 15 (5.6) 2 (3.0) 8 (22.2)
France 24 (6.4) 14 (5.2) 6 (9.0) 4 (11.1)
The Netherlands 11 (2.9) 7 (2.6) 4 (6.0) 0 (0.0)
Rest of Europe 22 (5.9) 16 (6.0) 3 (4.5) 3 (8.3)
Rest of the world 21 (5.6) 8 (3.0) 4 (6.0) 7 (19.4)
Psoriasis phenotype, no. (%) 1
Plaque 365 (97.9) 263 (98.5) 63 (94.0) 35 (100.0)
Pustular 8 (2.1) 4 (1.5) 4 (6.0) 0 (0.0)
Psoriatic arthritis, no. (%) 0
No 238 (63.6) 162 (60.7) 48 (71.6) 26 (72.2)
Yes 96 (25.7) 78 (29.2) 15 (22.4) 1 (2.8)
Unknown 40 (10.7) 27 (10.1) 4 (6.0) 9 (25.0)
Baseline psoriasis severity (per PGA), no. (%) 1
Clear 87 (23.3) 72 (27.0) 9 (13.4) 5 (14.3)
Nearly clear 113 (30.3) 99 (37.1) 6 (9.0) 7 (20.0)
Mild 98 (26.3) 59 (22.1) 27 (40.3) 11 (31.4)
Moderate 51 (13.7) 22 (8.2) 21 (31.3) 7 (20.0)
Moderate-to-severe 18 (4.8) 11 (4.1) 4 (6.0) 3 (8.6)
Severe 6 (1.6) 4 (1.5) 0 (0.0) 2 (5.7)
Time receiving treatment (mo), median (IQR) 24.0 (9.2-49.7) 23.2 (9.3-48.2) 25.8 (9.2-65.6) — 21
Treatment stopped during COVID-19, no. (%) 0
Yes 185 (55.4) 143 (53.6) 42 (62.7) —
No 139 (41.6) 117 (43.8) 22 (32.8) —
Unknown 10 (3.0) 7 (2.6) 3 (4.5) —
Biologic type, no. (%) 0
TNF inhibitor 99 (37.1) 99 (37.1) — —
IL-23 inhibitor 90 (33.7) 90 (33.7) — —
IL-17 inhibitor 78 (29.2) 78 (29.2) — —
Measures of obesity
BMI, median (IQR) 27.4 (24.8-33.1) 28.4 (25.1-34.2) 27.5 (23.8-32.0) 25.6 (23.9-26.9) 73
Obesity, no. (%) 123 (32.9) 96 (36.0) 22 (32.8) 5 (13.9) 0
Comorbidities, no. (%)
Hypertension 97 (25.9) 71 (26.6) 18 (26.9) 7 (19.4) 0
Diabetes 61 (16.3) 44 (16.5) 11 (16.4) 6 (16.7) 0
Anxiety or depression 40 (10.7) 27 (10.1) 9 (13.4) 3 (8.3) 0
Cardiovascular disease 36 (9.6) 21 (7.9) 9 (13.4) 6 (16.7) 0
Chronic liver disease 31 (8.3) 24 (9.0) 3 (4.5) 3 (8.3) 0
Asthma 25 (6.7) 18 (6.7) 6 (9.0) 1 (2.8) 0
Cancer (including remission) 15 (4.0) 8 (3.0) 4 (6.0) 3 (8.3) 0
COPD or other chronic lung disease 14 (3.7) 11 (4.1) 1 (1.5) 2 (5.6) 0
Chronic kidney disease 9 (2.4) 5 (1.9) 3 (4.5) 1 (2.8) 0
Alcohol excess 8 (2.1) 4 (1.5) 3 (4.5) 1 (2.8) 0
ACEI at onset, no. (%) 41 (12.8) 31 (13.4) 6 (10.0) 3 (12.5) 54
ARB at onset, no. (%) 41 (12.7) 27 (11.5) 11 (18.0) 2 (8.3) 50
NSAID at onset, no. (%) 26 (8.3) 19 (8.4) 3 (5.1) 2 (8.3) 60
(Continued)
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no systemic agent Missing
(no.)(n 5 374) (n 5 267) (n 5 67) (n 5 36)
Smoking, no. (%) 70
Current smoker 44 (14.5) 34 (15.5) 7 (13.5) 3 (10.0)
Former smoker 95 (31.2) 66 (30.1) 19 (36.5) 9 (30.0)
Never smoked 165 (54.3) 119 (54.3) 26 (50.0) 18 (60.0)
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; NSAID, nonsteroidal anti-inflammatory
drug; PGA, Physician’s Global Assessment.
Four participants have been excluded from the treatment groups because of unknown drug (clinical trial). The category biologics includes participants reporting cotherapy with
conventional systemic agents or steroids (n 5 15), small-molecule inhibitor (n 5 0), or both (n 5 0).
The category nonbiologic systemic therapy includes participants reporting use of conventional systemic agents or steroids (n5 39), small-molecule inhibitor (n5 26), or both (n5
2). Plaque psoriasis phenotype includes 1 patient with erythroderma and 3 with plaque and erythroderma. Pustular psoriasis phenotype includes 3 with plaque and/or erythroderma
also present. A total of 13 records imported directly from the American Academy of Dermatology COVID-19 (AAD COVID-19) registry were assumed to be records of patients
with plaque psoriasis. For patients receiving multiple systemic therapies, time receiving treatment was measured from the latest date (ie, start of cotherapy). For patients receiving
multiple systemic therapies, treatment stoppage was taken as stopping any of the treatments. The category obesity combines patients for whom obesity is selected as a comorbidity
with patients having a BMI of 30 or higher; it may therefore miss some of the 73 patients for whom BMI is not available.
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likely inflated because most hospitalized patients had confirmed
COVID-19 (69 of 76 [91%]).
To assess potential differences in COVID-19 hospitalization
risk between classes of biologics, we fitted a multiple logistic
regression model in which biologics were split into TNF, IL-23,
and IL-17 inhibitor groups (n5 98, 89, and 78, respectively) (see
Table E10 in this article’s Online Repository at www.jacionline.
org). Hospitalization was observed more frequently in patients
receiving IL-23 inhibitors (23%) than in those receiving TNF
(14%) or IL-17 inhibitors (13%); a fully adjusted odds ratio of
1.65 for the IL-23 inhibitor group was estimated relative to the
group receiving a TNF inhibitor. However, the 95% CI was
wide (0.64-4.25), and the split by biologic type did not signifi-
cantly improve model fit (P 5 .48).
The limited numbers of patients using combination therapy or
any individual agent precluded analysis of their association with
hospitalization.Risk-mitigating behaviors may vary between
patients with psoriasis receiving biologics and
those receiving nonbiologic systemic therapies
To help inform our interpretation of hospitalization rates
among patients with psoriasis who were receiving different types
of therapy, we investigated potential differences in COVID-19
risk-mitigating behaviors. Self-reported data from 1626 individ-
uals with psoriasis (with and without COVID-19) from 48
countries were available (see Table E3). Baseline characteristics,
including demographics, psoriasis phenotype, and comorbidities,
are summarized in Table IV. These were similar to characteristics
in the clinician-reported registry, except for sex (a female pre-
dominance of 64%in the self-report registry). Of 96 patients
(6%) who self-reported suspected or confirmed COVID-19, 25
(26%) were receiving a biologic, 13 (14%) were receiving a
nonbiologic systemic agent, and 58 (60%) were receiving no
treatment.
To assess baseline risk-mitigating behaviors, we interrogated
self-reported data from individuals without COVID-19 infection
(n 5 1476). In all, 478 individuals (32%) reported receiving
a biologic and 249 (17%) reported receiving a nonbiologic
systemic agent for psoriasis during the pandemic. Individuals inboth treatment groups had similar baseline characteristics, such as
age, ethnicity, and comorbidity rates (including obesity, hyper-
tension, cardiovascular disease, and psoriatic arthritis). Reported
rates of social isolation (shielding [ie, quarantine and distancing
within the home] or self-isolation [ie, staying home and avoiding
others]) were higher in those receiving biologics for psoriasis
(346 of 478 [72%]) than in those receiving nonbiologic systemic
therapies (161 of 249 [65%]; age- and sex-adjusted OR 5 0.68;
95% CI 5 0.50-0.94) and those receiving no systemic therapy
(470 of 747 [63%]; OR 5 0.63; 95% CI 5 0.50-0.80). However,
rates of treatment nonadherence were slightly lower, with 17% of
those receiving biologics (n 5 79) and 20% of those receiving
nonbiologic systemic therapies (n 5 48) reporting stopping
treatment during the pandemic. These independent patient-
reported data suggest that there may be potential variation in
COVID-19 risk–mitigating behavior between treatment groups.DISCUSSION
Summary of main findings
We have presented the largest and first global case series of
COVID-19 in people with psoriasis. Of 374 patients from 25
countries reported by clinicians, 93% fully recovered from
COVID-19. Older age, male sex, and nonwhite ethnicity were
associated with greater risk of hospitalization for COVID-19, in
addition to chronic lung disease. Comorbidities such as hyper-
tension, cardiovascular disease, and chronic liver disease were
more prevalent in hospitalized patients than in those not hospi-
talized. Our data also indicate an association between use of
biologics for psoriasis and reduced risk of hospitalization
compared with the risk associated with nonbiologic systemic
therapies. We cannot exclude the possibility that unmeasured
confounders may be driving this association: for example, our
patient-reported data (1626 participants across 48 countries)
suggest that COVID-19 risk-mitigating behaviors (social isola-
tion) may differ between psoriasis treatment groups. Finally, no
significant differencewas found in risk of hospitalization between
different classes of biologics. Further investigation of the higher
rate of hospitalization observed among patients using IL-23
inhibitors (compared with TNF or IL-17 inhibitors) in larger data
sets is warranted.














(n 5 67) (n 5 36) n
COVID-19 diagnosis, no. (%) 0
Suspected 202 (54.0) 154 (57.7) 33 (49.3) 15 (41.7)
Confirmed 172 (46.0) 113 (42.3) 34 (50.7) 21 (58.3)
COVID-19 outcome, no. (%) 0
Unresolved 4 (1.1) 2 (0.7) 2 (3.0) 0 (0.0)
Recovery 348 (93.0) 254 (95.1) 60 (89.6) 30 (83.3)
Chronic complication 13 (3.5) 7 (2.6) 2 (3.0) 4 (11.1)
Death 9 (2.4) 4 (1.5) 3 (4.5) 2 (5.6)
Hospitalization, no. (%) 4
Hospitalized 77 (20.8) 44 (16.6) 22 (33.8) 10 (27.8)
Not hospitalized 292 (78.9) 221 (83.4) 43 (66.2) 25 (69.4)
Unknown 1 (0.3) 0 (0.0) 0 (0.0) 1 (2.8)
Level of hospital care, no. (%)
No supplementary oxygen 8 (2.2) 4 (1.5) 1 (1.5) 3 (8.6) 5
Oxygen via mask 42 (11.4) 20 (7.5) 16 (24.6) 6 (17.1) 5
Noninvasive ventilation/hi flow 7 (1.9) 5 (1.9) 2 (3.1) 0 (0.0) 5
Mechanical ventilation 12 (3.3) 9 (3.4) 3 (4.6) 0 (0.0) 5
Ventilation (unknown type) 3 (0.8) 3 (1.1) 0 (0.0) 0 (0.0) 5
Unknown interventions 8 (2.2) 5 (1.9) 1 (1.5) 1 (2.9) 5
Composite outcome: mechanical ventilation or death, no. (%) 20 (5.4) 12 (4.5) 6 (9.2) 2 (5.6) 4
Duration of hospitalization (d), median (IQR) 11 (6-20) 14 (6-23) 10 (5-19) 10 (8-18) 13
Asymptomatic, no. (%) 12 (3.2) 9 (3.4) 1 (1.5) 2 (5.6) 4
Common COVID-19 symptoms (% among symptomatic
cases), no. (%)
Fever 244 (69.7) 168 (67.5) 51 (81.0) 22 (64.7) 12
Fatigue (malaise) 174 (49.7) 123 (49.4) 35 (55.6) 15 (44.1) 12
Dry continuous cough 167 (47.7) 119 (47.8) 31 (49.2) 15 (44.1) 12
Muscle aches (myalgia) 130 (37.1) 92 (36.9) 21 (33.3) 15 (44.1) 12
Shortness of breath (dyspnea) 116 (33.1) 87 (34.9) 18 (28.6) 10 (29.4) 12
Anosmia and/or dysgeusia 83 (23.7) 62 (24.9) 13 (20.6) 8 (23.5) 12
Joint pain (arthralgia) 64 (18.3) 49 (19.7) 11 (17.5) 2 (5.9) 12
Sore throat 62 (17.7) 45 (18.1) 14 (22.2) 3 (8.8) 12
Headache 49 (14.0) 39 (15.7) 7 (11.1) 3 (8.8) 12
Diarrhea 42 (12.0) 23 (9.2) 16 (25.4) 3 (8.8) 12
Chest pain 31 (8.9) 25 (10.0) 4 (6.3) 1 (2.9) 12
Cough with sputum production 26 (7.4) 20 (8.0) 5 (7.9) 0 (0.0) 12
Runny nose (rhinorrhea) 26 (7.4) 20 (8.0) 1 (1.6) 5 (14.7) 12
Wheezing 25 (7.1) 20 (8.0) 3 (4.8) 2 (5.9) 12
Nausea and/or vomiting 20 (5.7) 9 (3.6) 6 (9.5) 5 (14.7) 12
Abdominal pain 13 (3.7) 9 (3.6) 1 (1.6) 3 (8.8) 12
Conjunctivitis 10 (2.9) 8 (3.2) 1 (1.6) 1 (2.9) 12
Duration of COVID-19 symptoms, (d), median (IQR) 14 (7-21) 14 (7-21) 14 (10-22) 10 (7-18) 18
Four participants have been excluded from the treatment groups because of unknown drug (clinical trial). The category biologics includes participants reporting cotherapy with
conventional systemic agents or steroids (n5 15), small-molecule inhibitor (n5 0), or both (n5 0). The category nonbiologic systemic therapy includes participants reporting use
of conventional systemic agents or steroids (n 5 39), small-molecule inhibitor (n 5 26), or both (n 5 2). Four patients with unresolved COVID-19 have been excluded from the
COVID-19 outcome summaries (treated as missing). The symptom unspecified cough has been allocated to the category dry continuous cough (n 5 2 patients).
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The baseline characteristics of our international case series
suggest that our findings are likely to be applicable to people with
moderate-to-severe psoriasis because 90% of those reported were
taking systemic therapies and there was a high prevalence of
comorbidities.7,35 Our study underscores older age, male sex,
nonwhite ethnicity, and comorbidities as important risk factors
for adverse COVID-19 outcomes in people with psoriasis, which
is consistent with those risk factors already established for the
general population.2,6 A cohort study of 17 million adults in the
United Kingdom found that death from COVID-19 was associ-
ated with comorbidities, including cardiovascular disease,diabetes, obesity, reduced kidney function, and chronic liver dis-
ease.6 Similarly, a case series of 44,672 patients with COVID-19
in China showed that cardiovascular disease, hypertension, and
diabetes were risk factors for death.4 There are very limited
data on psoriasis, with 4 regional psoriasis case series in Northern
Italy, suggesting no increased rate of hospitalization or death from
COVID-19 in those receiving biologics compared with the rates
among the local population.17-20 Only 6 patients were hospital-
ized across the 4 reports, with few patients with nonsevere
COVID-19 captured (n5 517; n5 818; n not reported19,20); hence,
risk factors for adverse COVID-19 outcome could not be charac-
terized.We addressed this through a larger collection of cases that





model OR (95% CI) Fully adjusted model OR (95% CI)
Treatment type
Biologic 44/265 (16.6) Ref Ref
Nonbiologic systemic 22/65 (33.8) 2.72 (1.37-5.40) 2.84 (1.31-6.18)
No systemic agent 10/35 (28.6) 1.88 (0.75-4.68) 2.35 (0.82-6.72)
Male 58/220 (26.4) 2.29 (1.22-4.32) 2.51 (1.23-5.12)
Age (effect per 10 y) — 2.01 (1.59-2.52) 1.59 (1.19-2.13)
Nonwhite ethnicity 17/53 (32.1) 3.15 (1.24-8.03)
Assessment country
United Kingdom 19/133 (14.3) — Ref
Spain 23/53 (43.4) — 4.79 (1.88-12.19)
Rest of Europe 23/136 (16.9) — 1.61 (0.70-3.72)
Rest of the world 11/43 (25.6) — 1.27 (0.43-3.79)
BMI (effect per 5 kg/m2) — — 1.09 (0.87-1.37)
Hypertension 38/93 (40.9) — 2.03 (0.99-4.16)
Cardiovascular disease 20/34 (58.8) — 2.01 (0.74-5.46)
Chronic liver disease 14/30 (46.7) — 2.12 (0.81-5.55)
Diabetes 22/60 (36.7) — 1.05 (0.46-2.38)
Chronic lung disease (including asthma and COPD) 16/38 (42.1) — 3.87 (1.52-9.83)
Other comorbidities 30/77 (39.0) — 1.69 (0.83-3.43)
Ever smoked 34/136 (25.0) — 1.16 (0.54-2.49)
COPD, Chronic obstructive pulmonary disease; Ref, reference (refers to the reference group in the multivariable logistic regression models).
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and COVID-19 severity and outcomes. The comprehensive cap-
ture of clinician-reported demographic and clinical variables
enabled adjustment for important covariates in our logistic regres-
sion analysis.
Our finding of differential hospitalization risk associated with
different treatment groups builds on the emerging literature across
IMIDs. A recent single-center COVID-19 case series of 86
patients with IMIDs from New York (14 of whom had psoriasis)
observed that use of biologics was lower among those hospital-
ized for COVID-19 (6 of 14 [43%]) than among those not
hospitalized (50 of 72 [69%]).36 Use of nonbiologic systemic
agents, including the common psoriasis therapy methotrexate,
was higher among hospitalized patients than among those not
hospitalized.
Our data also align with findings from global clinician-
reporting COVID-19 registries in inflammatory bowel disease
(IBD) (525 patients across 33 countries) and rheumatic disease
(600 patients across 40 countries).28,29 The hospitalization and
case fatality rates were 31% and 3%, respectively, in IBD, and
46% and 9%, respectively, in rheumatic disease (vs 21% and
2% in our psoriasis data set). Severe COVID-19 was associated
with older age and comorbidities in both studies. TNF inhibitor
usewas associated with decreased risk of COVID-19–related hos-
pitalization among patients with rheumatic disease (OR 5 0.4;
95% CI 5 0.19-0.81) and decreased risk of hospitalization or
death among those with IBD (OR 5 0.6; 95% CI 5 0.38-0.96).
These findings, together with our data, contrast with pre–
COVID-19 observational data, in which use of biologics
(including TNF inhibitors) was associated with an increased
risk of serious infections (eg, a higher incidence of lower respira-
tory tract infections and/or pneumonia has been observed for in-
fliximab compared with methotrexate).10,11 A meta-estimate of
phase III randomized controlled trials of IL-17 inhibitors in
psoriasis also indicated an increased risk of respiratory tract infec-
tions compared with placebo (OR 5 1.31; 95% CI 5 1.05-1.62)37; however, a similar analysis (albeit it with smaller sample
sizes) found no statistically significant signal associated with IL-
23 inhibitor use (OR5 1.15; 95% CI 0.88-1.49).38 Phase III trial
data also suggest that use of psoriasis biologics (TNF, IL-17, and
IL-23 inhibitors) is not associated with increases in rates of viral
infections such as influenza compared with placebo,39 which is
consistent with the data from long-term registries10 and studies
of other IMIDs.40
Given the cytokine upregulation from aberrant immune
activation observed in severe COVID-19, there is biologic
plausibility for a protective effect of cytokine-targeted biologics
on adverse outcomes, compared with the effect of broader
immunosuppressants that may detrimentally suppress host anti-
viral immunity.41 This notion is currently under evaluation in tri-
als of repurposed IMID biologics in patients with COVID-19.42
Existing reports of elevated plasma levels of TNF and IL-17 in pa-
tients manifesting severe COVID-1931 also align with our obser-
vation of a lower hospitalization rate in individuals receiving TNF
inhibitors or IL-17 inhibitors compared with the rate in those
receiving IL-23 inhibitors. Given the close interplay between
IL-17 and IL-23 cytokines (IL-23 promotes the terminal differen-
tiation, proliferation, and activation of IL-17–secreting TH17
cells43) and the more established role of the IL-23/IL-17 axis in
bacterial and fungal immunity (as opposed to viral defense), these
observations require further study. We were unable to draw firm
conclusions because our sample numbers limited the power to
detect all but large differences in hospitalization risk between bio-
logic classes. Inhibitors of TNF, IL-17, and IL-23 are widely used
for the treatment of moderate-to-severe psoriasis, so further
accrual of cases over time will enable more robust interrogation
of the differential risks associated with different biologic classes,
which has important implications for clinical practice.
Alternatively, the association between use of biologics and
reduced hospitalization may not be causal but may instead be due
to unmeasured confounders. Our patient-reported data suggest
increased risk-mitigating behavior (social isolation) in














(n 5 1626) (n 5 512) (n 5 273) (n 5 839) n
COVID-19 infection, no. (%) 0
Yes, with test 15 (0.9) 1 (0.2) 2 (0.7) 12 (1.4)
Yes, no test 81 (5.0) 24 (4.7) 11 (4.0) 46 (5.5)
Unsure 54 (3.3) 9 (1.8) 11 (4.0) 34 (4.1)
No 1476 (90.8) 478 (93.4) 249 (91.2) 747 (89.0)
Age (y), median (range) 48 (36-59) 49 (39-58) 50 (38-60) 46 (33-60) 0
Sex, no. (%) 0
Female 1041 (64.0) 287 (56.1) 184 (67.4) 570 (67.9)
Male 583 (35.9) 223 (43.6) 89 (32.6) 269 (32.1)
Unknown 2 (0.1) 2 (0.4) 0 (0.0) 0 (0.0)
Ethnicity, no. (%) 19
White 1399 (87.1) 436 (85.8) 231 (85.2) 730 (88.4)
Nonwhite 208 (12.9) 72 (14.2) 40 (14.8) 96 (11.6)
Country of assessment, no. (%) 2
United Kingdom 1191 (73.3) 370 (72.3) 206 (75.5) 614 (73.4)
United States 98 (6.0) 48 (9.4) 11 (4.0) 39 (4.7)
Denmark 49 (3.0) 25 (4.9) 4 (1.5) 20 (2.4)
Sweden 33 (2.0) 10 (2.0) 7 (2.6) 16 (1.9)
Philippines 31 (1.9) 1 (0.2) 6 (2.2) 24 (2.9)
Canada 27 (1.7) 10 (2.0) 6 (2.2) 10 (1.2)
Ireland 26 (1.6) 8 (1.6) 1 (0.4) 17 (2.0)
Hong Kong 16 (1.0) 5 (1.0) 2 (0.7) 9 (1.1)
Norway 14 (0.9) 6 (1.2) 4 (1.5) 4 (0.5)
Australia 14 (0.9) 7 (1.4) 0 (0.0) 7 (0.8)
Singapore 11 (0.7) 0 (0.0) 4 (1.5) 7 (0.8)
Japan 10 (0.6) 7 (1.4) 2 (0.7) 1 (0.1)
Rest of Europe 53 (3.3) 9 (1.8) 4 (1.5) 40 (4.8)
Rest of the world 51 (3.1) 6 (1.2) 16 (5.9) 29 (3.5)
Psoriasis phenotype, no. (%) 20
Plaque 1446 (90.0) 457 (91.0) 232 (85.9) 755 (90.7)
Pustular 104 (6.5) 35 (7.0) 28 (10.4) 41 (4.9)
Unsure 56 (3.5) 10 (2.0) 10 (3.7) 36 (4.3)
Psoriatic arthritis, no. (%) 0
Yes 548 (33.7) 246 (48.0) 128 (46.9) 173 (20.6)
No 993 (61.1) 243 (47.5) 128 (46.9) 621 (74.0)
Unsure 85 (5.2) 23 (4.5) 17 (6.2) 45 (5.4)
Baseline psoriasis severity (self-reported using the
PGA scale), no. (%)
0
Clear 218 (13.4) 158 (30.9) 23 (8.4) 36 (4.3)
Nearly clear 364 (22.4) 184 (35.9) 60 (22.0) 119 (14.2)
Mild 423 (26.0) 88 (17.2) 68 (24.9) 267 (31.8)
Moderate 359 (22.1) 40 (7.8) 73 (26.7) 246 (29.3)
Moderate-to-severe 188 (11.6) 30 (5.9) 32 (11.7) 126 (15.0)
Severe 63 (3.9) 9 (1.8) 16 (5.9) 38 (4.5)
Not sure 11 (0.7) 3 (0.6) 1 (0.4) 7 (0.8)
Duration of treatment of group with COVID-19, at
onset (mo), median (range)
25.3 (6.0-51.0) 23.4 (9.2-49.8) 27.7 (2.9-51.9) — 11
Duration of treatment of uninfected group, at survey
date (mo), median (range)
25.2 (9.1-60.2) 24.8 (9.5-52.5) 26.1 (7.9-74.4) — 48
Treatment stopped during COVID-19, no. (%) 22 (40.7) 11 (35.5) 11 (47.8) — 4
Treatment stopped during pandemic (uninfected
group), no. (%)
127 (17.9) 79 (17.0) 48 (19.8) — 21
Biologic type, no. (%) 0
TNF inhibitor 225 (43.9) 225 (43.9) — —
IL-23 inhibitor 171 (33.4) 171 (33.4) — —
IL-17 inhibitor 115 (22.5) 115 (22.5) — —
IL-1R inhibitor 1 (0.2) 1 (0.2) — —
Measures of obesity
BMI (kg/m2), median (range) 26.8 (23.4-31.2) 27.9 (24.3-32.5) 26.6 (23.3-31.2) 26.0 (22.8-29.8) 114
Obesity, no. (%) 478 (29.4) 176 (34.4) 91 (33.3) 210 (25.0) 0
(Continued)
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(n 5 1626) (n 5 512) (n 5 273) (n 5 839) n
Comorbidities no. (%)
Hypertension 344 (21.2) 135 (26.4) 69 (25.3) 139 (16.6) 0
Diabetes 105 (6.5) 43 (8.4) 14 (5.1) 48 (5.7) 0
Anxiety or depression 384 (23.6) 120 (23.4) 58 (21.2) 206 (24.6) 0
Cardiovascular disease 95 (5.8) 26 (5.1) 17 (6.2) 52 (6.2) 0
Chronic liver disease 81 (5.0) 42 (8.2) 10 (3.7) 29 (3.5) 0
Asthma 181 (11.1) 66 (12.9) 25 (9.2) 90 (10.7) 0
Cancer (incl. remission) 43 (2.6) 10 (2.0) 6 (2.2) 27 (3.2) 0
COPD or other chronic lung disease 44 (2.7) 17 (3.3) 8 (2.9) 19 (2.3) 0
Chronic kidney disease 16 (1.0) 8 (1.6) 3 (1.1) 5 (0.6) 0
ACEI user, no. (%) 204 (13.9) 76 (16.8) 41 (16.9) 87 (11.3) 162
ARB user, no. (%) 140 (10.0) 62 (14.4) 22 (9.7) 55 (7.4) 219
NSAID user, no. (%) 288 (20.2) 112 (25.2) 39 (17.3) 137 (18.2) 202
Smoking, no. (%) 28
Never smoked 837 (52.4) 254 (50.3) 150 (55.8) 433 (52.7)
Former smoker 571 (35.7) 184 (36.4) 88 (32.7) 299 (36.4)
Current smoker 190 (11.9) 67 (13.3) 31 (11.5) 90 (10.9)
Risk-mitigating behaviors (uninfected group), no. (%)
Shielding 319 (21.6) 134 (28.0) 54 (21.7) 131 (17.5) 0
Self-isolating 831 (56.3) 273 (57.1) 130 (52.2) 426 (57.0) 0
Shielding or self-isolating 979 (66.3) 346 (72.4) 161 (64.7) 470 (62.9) 0
Social distancing 989 (67.0) 275 (57.5) 161 (64.7) 552 (73.9) 0
Wearing gloves or masks 555 (37.6) 190 (39.7) 87 (34.9) 278 (37.2) 0
Other risk-mitigating behavior 42 (2.8) 14 (2.9) 3 (1.2) 25 (3.3) 0
No risk-mitigating behavior 11 (0.7) 2 (0.4) 2 (0.8) 7 (0.9) 0
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; NSAID, nonsteroidal anti-inflammatory
drug; PGA, Physician’s Global Assessment.
Two participants have been excluded from the treatment groups because of unknown drug (clinical trial). The category biologics includes participants reporting cotherapy with
conventional systemic or steroids (n 5 61), small-molecule inhibitor (n 5 2), or both (n 5 3). The category nonbiologic systemic therapy includes participants reporting use of
conventional systemic or steroids (n 5229), small-molecule inhibitor (n 5 39), or both (n 5 6). Time receiving treatment and adherence data have been excluded for participants
reporting use of multiple biologics (n5 5), multiple conventional systemics or steroids (n 5 10), or multiple small-molecule inhibitors (n5 0). For participants reporting systemic
treatments in more than 1 category, time receiving treatment was measured from the latest date (ie, start of cotherapy). The category obesity combines participants selecting obesity
as a comorbidity with those having a BMI of 30 or higher; it may therefore miss some of the 114 participants for whom BMI is not available.
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receiving nonbiologic systemic agents, which may reflect public
perceptions of differential risk associated with different treat-
ments. Social isolation may influence the initial exposure dose of
SARS-CoV-2, which may affect the viral load and clinical course
of COVID-19. Behavioral variation between treatment groups
and the consequent impact on COVID-19 risk and/or severity
warrant urgent further investigation because it is potentially
relevant for public health policy.Strengths and limitations
Major strengths of this case series are its global reach and size.
The speed with which data have been accrued has enabled the
timely release of results in response to the current global public
health emergency. As the largest international study of COVID-
19 outcomes in patients with psoriasis, our findings are more
generalizable than those of the regional reports published to date.
The key demographic associations with hospitalization for
COVID-19 (sex, age, and ethnicity) in our psoriasis data set are
in keeping with prior findings in the general population, which
suggests robust data capture. We also present independent global
patient-reported data on risk-mitigating behaviors during the
pandemic, thus addressing for the first time a potential unmea-
sured confounder in clinician-reported data sets.Information on the registries was disseminated worldwide,
but the larger numbers of patients from Spain, Italy, and the
United Kingdom (albeit areas of high COVID-19 prevalence)
indicate potential ascertainment bias, which limits the gener-
alizability of the results. Although our hospitalization rate of
22% is comparable to that in other global IMID registries, more
severe COVID-19 cases may be overrepresented because these
may have been preferentially brought to the attention of
clinicians. In contrast, patients who have died or those
remaining in the hospital may not yet have been reported. The
higher hospitalization rate in Spain may represent a selective
capture of severe cases or different international thresholds for
hospital admission; the latter is a limitation of using hospital-
ization as a proxy for severe COVID-19. Reassuringly, a
sensitivity analysis excluding Spanish cases did not change
our conclusions, and differences in rates of death and mechan-
ical ventilation among patients with psoriasis receiving bi-
ologics versus among those receiving nonbiologic systemic
therapies were consistent with our primary findings for hospi-
talization. Diverse COVID-19 testing practices may also have
affected reporting (eg, preferential testing of severely ill and/or
hospitalized patients), although we encouraged submission of
suspected cases and our sensitivity analysis restricted to
patients with only confirmed COVID-19 yielded results to
similar those of the main analysis.
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severe psoriasis; therefore, our findings may not be generalizable
to those with milder psoriasis. The majority of clinician-reported
patients were receiving biologics, which contrasts with our
patient-reported data. If this represents a different propensity
for clinicians to report patients receiving different types of
treatment, then together with a higher likelihood of hospitalized
cases being reported, this could lead to inflated effect size
estimates on account of selection bias. In contrast to the
limitations of clinician-reported data, a potential limitation of
the self-report data set is exposure misclassification, but it is
reassuring that the overall baseline characteristics of both
registries are comparable.
Although not an objective of this study, the clinical course of
COVID-19 in individuals with and without psoriasis cannot be
compared owing to the lack of a matched control group from the
general population. COVID-19 outcomes in those receiving
biologics in our study also cannot be directly compared with
the outcomes studies of the general population because of
fundamental differences in the ascertainment of cases. However,
the observed median length of hospital stay and COVID-19
symptom characteristics in our biologic-treated clinician-re-
ported case series is similar to the median lengths published for
general populations. For example, the median length of hospital
stay for patients with psoriasis and COVID-19 who were
receiving biologics in our study (14 days [IQR 5 6-23 days]) is
similar to that of 1099 hospitalized patients with COVID-19
across 552 hospitals in China (12 days [IQR 5 10-14 days]).44
The 3 most common symptoms of COVID-19 in both the Chinese
cohort and our patients who were receiving psoriasis biologics
were fever, cough, and fatigue.
The incidence of COVID-19 in psoriasis cannot be determined
on account of the lack of denominator (source population) data
and uncertainty regarding those patients with psoriasis and
COVID-19 who were not reported. The incidence of COVID-19
in individuals receiving particular therapies also cannot be
deduced; however, future linkage to pharmacovigilance registry
data should facilitate this.Conclusions
In this large international series of patients with psoriasis and
COVID-19, use of biologics was associated with a reduced risk of
adverse COVID-19 outcome when compared with the risk
associated with use of nonbiologic systemic agents. This effect
appeared to be primarily associated with use of TNF and IL-17
inhibitors; however, further investigation of the observed
differential rate of hospitalization between different classes of
biologics is warranted. The accumulation of further data is
required to clarify these observations before any recommenda-
tions for changes in clinical practice can be considered. Possible
selection bias should be addressed through robust global clinician
and patient participation in COVID-19 registries and alternative
study designs such as cohort studies. This will open avenues for
characterizing the determinants of additional COVID-19
outcomes and the impact of specific treatments at higher
resolution.
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BSc, MRCP, Elena Hawryluk, MD, PhD, Eliseo Martınez-Garcıa, MD, PhD,
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dozo, MD, Ian Pearson, MRCP, Ignacio Yanguas, MD, Jamie Weisman, MD,
Jennifer E. Carolan, MSc, Jenny Hughes, FRCP, Jose-Maria Ortiz-Salvador,
MD, PhD, Jose-Manuel Carrascosa, MD, PhD, Joseph J Schwartz, MD, Kar-
ina Jackson,MSc, KathrynGKerisit,MD,MPH,KeithWu,MD, Leila Asfour,
MRCP, Leontien de Graaf, MD, Cecile Lesort, MD, Lieve Meuleman, MD,
Liv Eidsmo, MD, PhD, Lone Skov, MD, PhD, Lorraine Gribben, BSc,
Malcolm Rustin, MD, Manel Velasco, MD, Manisha Panchal, MD,
Manpreet Lakhan, MRCP, Manuel D. Franco, MD, Marie-Louise Svensson,
BSc, Mark Vandaele, MD, Maruska Marovt, MD, PhD, Omid Zargari, MD,
Pablo De Caso, MD, Paulo Varela, MD, Peter Jenkin, MD, FAAD,
Celine Phan, MD, Philip Hampton, FRCP, PhD, Portia Goldsmith, MD,
FRCP, Rachel Bak, MD, Reinhart Speeckaert, MD, PhD, Ricardo Romiti,
MD, PhD, Richard Woolf, MRCP, PhD, Rogelio Mercado-Seda, MD,
Rohima Khatun, BSc, Romana Ceovic, MD, Rosa Taberner, MD, Russell
W. Cohen, MD, FAAD, Simina Stefanescu, MD, Sarah Kirk, BSc,
Saskia Reeken, BSc, Shanti Ayob, MRCP, Silvia Perez-Barrio, MD, Stefano
Piaserico, MD, PhD, Susannah Hoey, MD, Tiago Torres, MD, PhD, Toomas
Talme, MD, PhD, Trupti V. Desai, MD, Adrienne J. van Geest, MD, Victoria
King, BSc, Vito Di Lernia, MD, Zahira Koreja, BSc, and Vito Zeeshaan
Hasab, MBBS.
Clinical implications: We identify risk factors for COVID-19–
related hospitalization in patients with psoriasis, including
older age, male sex, nonwhite ethnicity, and comorbidities.
Use of biologics was associated with lower hospitalization risk
than were nonbiologic systemic therapies, however further
study is required on account of potential selection bias and un-
measured confounding.REFERENCES
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